How Improvement in Control of Diabetes Influences the Production of a Hormone Produced in the Gut Which Improves the Release and Action of Insulin. (MSD-GLP1)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00747383|
Recruitment Status : Completed
First Posted : September 5, 2008
Last Update Posted : December 5, 2012
|Condition or disease||Intervention/treatment|
|Type 2 Diabetes Mellitus||Drug: Glimepiride Drug: Sitagliptin|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||74 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Double (Investigator, Outcomes Assessor)|
|Official Title:||Influence of Improving Glycaemic Control on Glucagon-Like-Peptide-1 Response to an Oral Glucose Load. Comparison of Sulphonylurea With DPP-4 Inhibition.|
|Study Start Date :||September 2008|
|Primary Completion Date :||September 2010|
|Study Completion Date :||September 2010|
|Active Comparator: 1||
3mg oral tablet.
Other Name: Amaryl.
|Active Comparator: 2||
100mg oral tablet.
Other Name: Januvia.
- Comparison of GLP-1 response at baseline and after 3 months treatment of both groups. [ Time Frame: 2 years ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00747383
|Royal Bournemouth Hospital|
|Bournemouth, Dorset, United Kingdom, BH7 7DW|
|Principal Investigator:||David Kerr||Royal Bournemouth Hospital|
|Principal Investigator:||Joseph Begley||Royal Bournemouth Hospital|